Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

94 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Modernizing Eligibility Criteria for Molecularly Driven Trials.
Kim ES, Bernstein D, Hilsenbeck SG, Chung CH, Dicker AP, Ersek JL, Stein S, Khuri FR, Burgess E, Hunt K, Ivy P, Bruinooge SS, Meropol N, Schilsky RL. Kim ES, et al. Among authors: ivy p. J Clin Oncol. 2015 Sep 1;33(25):2815-20. doi: 10.1200/JCO.2015.62.1854. Epub 2015 Jul 20. J Clin Oncol. 2015. PMID: 26195710
Glucarpidase, leucovorin, and thymidine for high-dose methotrexate-induced renal dysfunction: clinical and pharmacologic factors affecting outcome.
Widemann BC, Balis FM, Kim A, Boron M, Jayaprakash N, Shalabi A, O'Brien M, Eby M, Cole DE, Murphy RF, Fox E, Ivy P, Adamson PC. Widemann BC, et al. Among authors: ivy p. J Clin Oncol. 2010 Sep 1;28(25):3979-86. doi: 10.1200/JCO.2009.25.4540. Epub 2010 Aug 2. J Clin Oncol. 2010. PMID: 20679598 Free PMC article.
Novel designs and end points for phase II clinical trials.
Adjei AA, Christian M, Ivy P. Adjei AA, et al. Among authors: ivy p. Clin Cancer Res. 2009 Mar 15;15(6):1866-72. doi: 10.1158/1078-0432.CCR-08-2035. Epub 2009 Mar 10. Clin Cancer Res. 2009. PMID: 19276272 Review.
Phase II study of temsirolimus in women with recurrent or metastatic endometrial cancer: a trial of the NCIC Clinical Trials Group.
Oza AM, Elit L, Tsao MS, Kamel-Reid S, Biagi J, Provencher DM, Gotlieb WH, Hoskins PJ, Ghatage P, Tonkin KS, Mackay HJ, Mazurka J, Sederias J, Ivy P, Dancey JE, Eisenhauer EA. Oza AM, et al. Among authors: ivy p. J Clin Oncol. 2011 Aug 20;29(24):3278-85. doi: 10.1200/JCO.2010.34.1578. Epub 2011 Jul 25. J Clin Oncol. 2011. PMID: 21788564 Free PMC article. Clinical Trial.
Cediranib, an oral inhibitor of vascular endothelial growth factor receptor kinases, is an active drug in recurrent epithelial ovarian, fallopian tube, and peritoneal cancer.
Matulonis UA, Berlin S, Ivy P, Tyburski K, Krasner C, Zarwan C, Berkenblit A, Campos S, Horowitz N, Cannistra SA, Lee H, Lee J, Roche M, Hill M, Whalen C, Sullivan L, Tran C, Humphreys BD, Penson RT. Matulonis UA, et al. Among authors: ivy p. J Clin Oncol. 2009 Nov 20;27(33):5601-6. doi: 10.1200/JCO.2009.23.2777. Epub 2009 Oct 13. J Clin Oncol. 2009. PMID: 19826113 Free PMC article. Clinical Trial.
Randomized phase II designs.
Rubinstein L, Crowley J, Ivy P, Leblanc M, Sargent D. Rubinstein L, et al. Among authors: ivy p. Clin Cancer Res. 2009 Mar 15;15(6):1883-90. doi: 10.1158/1078-0432.CCR-08-2031. Epub 2009 Mar 10. Clin Cancer Res. 2009. PMID: 19276275 Free PMC article. Review.
94 results